MKI67 and breast cancer: Patients with HER2-low BC had fewer grade III statuses, lower proliferation (Ki67>35), and fewer TP53 mutations compared to those with HER2-zero tumors.33 Additionally, patients with HER2-low BC exhibited a reduced pathologic complete response (pCR) rate, particularly in patients with HR+ status.